跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CABLIVI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
CABLIVI
Authorized
STANDARD
CABLIVI
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
04f03dd67c64d61a
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
04f03dd67c64d61a
Drug Approval Canada Name
CABLIVI
Product Name
CABLIVI
Status
Cancelled Post Market
Status Date
2025-01-14
Original Market Date
2020-09-04
Din
02496194
Drug Class
Human
Dosage Form
Powder For Solution , Kit
Route Of Administration
Subcutaneous , Intravenous
Schedule
Schedule D , Prescription
Ahfs
20:12.92
Atc Original
B01AX07 CAPLACIZUMAB
Atc Name
b 01 ax 07
Aig Number
0162033001
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
CAPLACIZUMAB
11 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
04f03dd67c64d61a
Type
Standard
Back to Health Canada Approvals